ConductScience.org, home

Comparison · NCT02861534-91f52edb

Vericiguat vs Placebo: Number of Participants Who Discontinued Treatment Due to an Adverse Event

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Vericiguat vs Placebo: Number of Participants Who Discontinued Treatment Due to an Adverse Event. Trial comparisons, record NCT02861534-91f52edb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02861534-91f52edb

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.06630.05720.0767wilson
Risk in group 20.06280.0540.073wilson
Risk difference, group 1 minus group 20.00347-0.01020.0171newcombe hybrid score
Risk ratio, group 1 over group 21.060.8551.3log
Odds ratio, group 1 over group 21.060.8461.33log
Number needed to treat, for one more participant with the outcome on Vericiguat than on Placebo288from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1VericiguatParticipants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose was uptitrated to 5 mg and to 10 mg.1672,519OG000
Group 2Placebo
Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 mg.
1582,515OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Discontinued Treatment Due to an Adverse Event
Description
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame
Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)
Population
All randomized participants who received at least 1 dose of study treatment

Source ClinicalTrials.gov

Trial

Title
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
NCT number
NCT02861534
Phases
PHASE3
Conditions
Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Vericiguat, Placebo for vericiguat
Lead sponsor
Merck Sharp & Dohme LLC
Results first posted
2020-06-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02861534-91f52edb